KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Gains from Investment Securities (2016 - 2025)

Acadia Pharmaceuticals (ACAD) has 12 years of Gains from Investment Securities data on record, last reported at $12.5 million in Q3 2025.

  • For Q3 2025, Gains from Investment Securities changed N/A year-over-year to $12.5 million; the TTM value through Sep 2025 reached $12.5 million, changed N/A, while the annual FY2024 figure was $19.5 million, 233.69% up from the prior year.
  • Gains from Investment Securities reached $12.5 million in Q3 2025 per ACAD's latest filing, down from $15.1 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $15.1 million in Q4 2021 and bottomed at $12.5 million in Q3 2025.